Trial drug shows 'impressive' Alzheimer's action: study

August 31, 2016

Credit: Sevigny et al
An experimental drug cleared protein buildup in the brains of people with mild Alzheimer's disease and slowed their mental decline, the results of a preliminary trial showed Wednesday.

The outcome raised hopes that a treatment may finally be within reach for the memory- and independence-robbing disease, but experts cautioned against overplaying the findings.

The drug, aducanumab, is only the latest antibody to show promise in an early, Phase I drug trial, they said. Others ended up disappointing in the decisive Phase III efficacy test.

"Although potentially this is an exciting story, it is important to temper any excitement with considerable caution," said Robert Howard, a professor of old age psychiatry at University College London.

"It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer's disease."

Researchers in the United States and Switzerland tested aducanumab, developed by biotech firm Biogen, on 165 people with early-stage Alzheimer's disease for a period of one year.

Some were given a monthly injection of the antibody, and others a placebo or dummy drug.

In the brains of those given the treatment, there was an "almost complete clearance" of so-called amyloid plaques, the researchers reported.

Amyloids are sticky proteins that clump together in deposits—one of the mechanisms suspected of causing Alzheimer's.

"The effect of the antibody is very impressive," said Roger Nitsch, a professor at the University of Zurich's Institute for Regenerative Medicine, who co-authored the study.

'Now is the time'

After one year of treatment, "practically no beta-amyloid plaques could be detected in patients who received the highest dose," said a university statement.

And while the trial was not designed to test drug efficacy, the team did observe slower onset of symptoms in treated patients.

This supported the hypothesis that amyloid plaques are indeed what cause Alzheimer's, the researchers said, but further tests are required to prove this once and for all.

"Indeed, confirmation that anti-AB (amyloid-beta) treatment slows cognitive decline would be a game-changer for how we understand, treat and prevent Alzheimer's disease," commented Eric Reiman at the Banner Alzheimer's Institue in Phoenix, Arizona.

"Now is the time to find out."

The drug did have side-effects, however, including fluid buildup on the brain, and headaches.

Alzheimer's disease is the most common form of dementia, which the World Health Organisation (WHO) says affects nearly 50 million people worldwide—with some 7.7 million new cases diagnosed per year.

Old age is the major risk factor, and there is no prevention or effective treatment for Alzheimer's symptoms, which include memory loss and disorientation, as well as anxiety and aggressive behaviour.

Like actor Gene Wilder, who passed away on Monday, people do not die of Alzheimer's itself but complications which can include infections or malnutrition.

Last year, drug-maker Eli Lilly said the drug solanezumab, also an antibody, showed promise when given to people in the early stages of Alzheimer's.

Results from further testing with both drugs will be hotly anticipated in the months to come.

Outside experts expressed cautious optimism about the new study, published in the journal Nature.

"Let's keep our fingers crossed for success in the next steps," said neuroscience professor Richard Morris from the University of Edinburgh.

Explore further: Possible solution for side effect of Alzheimer's immunotherapy treatment

More information: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, Nature, nature.com/articles/doi:10.1038/nature19323

Related Stories

Possible solution for side effect of Alzheimer's immunotherapy treatment

November 5, 2015
It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

Promising new methods for early detection of Alzheimer's disease

July 8, 2016
New methods to examine the brain and spinal fluid heighten the chance of early diagnosis of Alzheimer's disease. Results from a large European study, led by researchers at the Karolinska Institutet, are now published in the ...

Study shows antibody therapy clears Alzheimer's plaques in mice

December 5, 2012
Antibodies against amyloid beta (Aβ) protein deposits that are thought to play a role in Alzheimer's disease have shown some success in preventing the buildup of deposits in animals, but they have not been effective at removing ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Alzheimer's: Nicotinic receptors as a new therapeutic target

August 29, 2016
Several scientific studies have indicated that nicotine may be beneficial for memory function. Scientists from the Institut Pasteur and the CNRS set out to shed further light on the properties attributed to nicotine - which ...

PET imaging with special tracer can detect and diagnose early Alzheimer's disease

May 24, 2016
The effort to find ways to detect and diagnose preclinical Alzheimer's disease (AD) has taken a big step forward with the use of positron emission tomography (PET), a "nuclear medicine" for imaging processes in the body, ...

Recommended for you

Hypothesis underpinning dementia research 'flawed'

October 16, 2018
A hypothesis which has been the standard way of explaining how the body develops Alzheimer's Disease for almost 30 years is flawed, according to a University of Manchester biologist.

Study suggests biological basis for depression, anxiety, sleep disturbances in older adults

October 15, 2018
UC San Francisco researchers, in collaboration with the unique Brazilian Biobank for Aging Studies (BBAS) at the University of São Paulo, have shown that the earliest stages of the brain degeneration associated with Alzheimer's ...

Many cases of dementia may arise from non-inherited DNA 'spelling mistakes'

October 15, 2018
Only a small proportion of cases of dementia are thought to be inherited—the cause of the vast majority is unknown. Now, in a study published today in the journal Nature Communications, a team of scientists led by researchers ...

Scientists create new map of brain region linked to Alzheimer's disease

October 8, 2018
Curing some of the most vexing diseases first requires navigating the world's most complex structure—the human brain. So, USC scientists have created the most detailed atlas yet of the brain's memory bank.

Previously unknown genetic aberrations found to be associated with Alzheimer's progression

October 8, 2018
In a large-scale analysis of RNA from postmortem human brain tissue, researchers at the Icahn School of Medicine at Mount Sinai and Columbia University have identified specific RNA splicing events associated with Alzheimer's ...

Periodontal disease bacteria may kick-start Alzheimer's

October 4, 2018
Long-term exposure to periodontal disease bacteria causes inflammation and degeneration of brain neurons in mice that is similar to the effects of Alzheimer's disease in humans, according to a new study from researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.